Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19)

Laine E Thomas^{1

2

3}, Robert O Bonow^{4

5}, Michael J Pencina^{1

2

6}

Affiliations

¹ Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
² Duke Clinical Research Institute, Durham, North Carolina.
³ Assistant Editor.
⁴ Northwestern University Feinberg School of Medicine, Chicago, Illinois.
⁵ Editor.
⁶ Deputy Editor.

Editorial

Laine E Thomas et al. JAMA Cardiol. 2020.

. 2020 Sep 1;5(9):988-990.

doi: 10.1001/jamacardio.2020.1874.

Laine E Thomas^{1

2

3}, Robert O Bonow^{4

5}, Michael J Pencina^{1

2

6}

¹ Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
² Duke Clinical Research Institute, Durham, North Carolina.
³ Assistant Editor.
⁴ Northwestern University Feinberg School of Medicine, Chicago, Illinois.
⁵ Editor.
⁶ Deputy Editor.

No abstract available

Comment on

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK. Mehta N, et al. JAMA Cardiol. 2020 Sep 1;5(9):1020-1026. doi: 10.1001/jamacardio.2020.1855. JAMA Cardiol. 2020. PMID: 32936273 Free PMC article.